ARS Pharmaceuticals Operations, Inc.

ARS Pharmaceuticals Operations, Inc. is a biopharmaceutical company founded in 2015 and headquartered in San Diego, California. It develops needle-free epinephrine products intended to change how severe allergic reactions, including anaphylaxis, are treated. The company's work spans drug development, nasal spray formulation and emergency medicine therapeutics.

Its lead product, neffy, is the first and only FDA-approved needle-free epinephrine nasal spray for the emergency treatment of allergic reactions including anaphylaxis, approved for adults and children aged 4 years and older. The formulation is designed to remove the needle from emergency epinephrine delivery, addressing needle-related risk and the compliance problems associated with injectable devices.

Beyond the product itself, the company runs two access and education programmes. neffyconnect is a patient assistance programme established to improve affordability and access to neffy, while neffyinSchools provides eligible K-12 schools across the United States with free neffy for emergency use. The stated focus of the business is on at-risk patients and their caregivers, with an emphasis on affordability, community health and safety.

The company operates in the allergy and immunology, emergency medicine, pediatric healthcare and school health sectors. Technical work at ARS Pharmaceuticals covers biopharmaceutical drug development, needle-free drug delivery, nasal spray formulation and epinephrine delivery.